

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ	関連
1) 田中純子、秋田智之、杉山文	SDGs 目標のウイルス肝炎排除を目指したアジア・アフリカ地域の国際共同疫学研究：HBV に焦点を当てて	月刊「アグリバイオ」編集委員会	アグリバイオ	北隆館	東京	2023		○
2) 田中純子	わが国における HCV 感染症の疫学-最近の疫学と HCV elimination の見通し		臨床消化器内科	日本メディカルセンター	東京	2022		○
3) 田中純子、小山富子	肝炎ウイルス検診におけるアキュラシード HCV[II] の有用性評価		医学と薬学	自然科学出版	東京	2022		○
4) 田中純子、Ouoba Serge、E Bunthen	SDGs 目標のウイルス肝炎排除を目指したアジア・アフリカ地域の国際共同疫学研究：HBV に焦点を当てて	月刊「アグリバイオ」編集委員会	アグリバイオ	北隆館	東京	2022		○
5) 相崎英樹	日本の感染症の発生状況	菅又昌実	日本の感染症—明らかにされたこと残された課題—	南山堂	東京	2022	13-34	○
6) 相崎英樹、青柳東代、杉山真也、村松正道、溝上雅史、脇田隆字	HCV 排除後の肝発癌における課題 HCV 駆除後発癌の基礎的考察—形態とゲノムからの考察—		臨床消化器内科	日本メディカルセンター	東京	2022	914-919	
7) 保坂哲也	HBV 増殖制御下の B 型肝炎における肝癌発生の現状とリスク因子	小池和彦	臨床消化器内科 8 月号	日本メディカルセンター	東京	2022	921	○
8) 保坂哲也	高感度 HB コア関連抗原測定の臨床的意義	消化器・肝臓内科編集委員会	消化器・肝臓内科 12 月号	科学評論社	東京	2022	670	○
9) 保坂哲也	B 型肝炎核酸アナログ治療下の発癌リスク評価	「肝胆膵」編集委員会	肝胆膵	アークメディア	東京	2022	79	○

発表者氏名		論文タイトル名	発表誌名	巻号	ページ	出版年	関連
1)	Imajo K, Toyoda H, Yasuda S, Suzuki Y, Sugimoto K, Kuroda H, Akita T, <a href="#">Tanaka J</a> , Yasui Y, Tamaki N, Kurosaki M, Izumi N, Nakajima A, Kumada T	Utility of ultrasound-guided attenuation parameter for grading steatosis with reference to MRI-PDFF in a large cohort	Clinical gastroenterology and hepatology	in press	in press	2023	
2)	Kurisu A, Sugiyama A, Akita T, Takumi I, Yamamoto H, Iida K, <a href="#">Tanaka J</a>	Incidence and prevalence of epilepsy in Japan: a retrospective analysis of insurance claims data of 9,864,278 insured persons	Journal of epidemiology	in press	in press	2023	
3)	Imada H, Akita T, Sugiyama A, <a href="#">Tanaka J</a>	Trend of blood donors entering the coronavirus pandemic era and challenges: Age-Period-Cohort analysis using 75.5 million all blood donations data during 2006-2020 in Japan	Transfusion	in press	in press	2023	
4)	Ichikawa H, Yasuda E, Kumada T, Takeshima K, Ogawa S, Tsunekawa A, Goto T, Nakaya K, Akita T, <a href="#">Tanaka J</a>	Intra-individual comparison of liver stiffness measurements by magnetic resonance elastography and two-dimensional shear-wave elastography in 888 patients	Ultrasonography	42(1)	65-77	2023	○
5)	Nobuhara H, Matsugu Y, <a href="#">Tanaka J</a> , Akita T, Ito K	The preventive effects of perioperative oral care on surgical site infections after pancreatic cancer surgery: a retrospective study	Support Care Cancer	30(4)	3337-3344	2022	
6)	Matsugu Y, Ito K, Oshita A, Nobuhara H, <a href="#">Tanaka J</a> , Akita T, Itamoto T	Postoperative oral energy and protein intakes for an enhanced recovery after surgery program incorporating early enteral nutrition for pancreaticoduodenectomy: A retrospective study	Nutrition in Clinical Practice	37(3)	654-665	2022	
7)	Hayes NC, Imamura M, <a href="#">Tanaka J</a> , Chayama K	Road to elimination of HCV: Clinical challenges in HCV management	Liver International	42(9)	1935-1944	2022	○
8)	Blach S, Terrault NA, Tacke F, et al, ( <a href="#">Tanaka J</a> 含む 259 人中 6 番目)	Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study	The LANCET Gastroenterology and Hepatology	7(5)	396-415	2022	○
9)	Toyoda H, Yasuda S, Shiota S, Kumada T, <a href="#">Tanaka J</a>	Adherence to regular surveillance visits for hepatocellular carcinoma in patients with chronic hepatitis C virus infection who achieved sustained virologic response	European Journal of Gastroenterology and Hepatology	34(6)	693-697	2022	○
10)	Kitagawa H, Kaiki Y, Sugiyama A, Ngashima S, Kurisu A, Nomura T, Omori K, Akita T, Shigemoto N, <a href="#">Tanaka J</a> , Ohge H	Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan	Journal of infection and chemotherapy	28(4)	576-581	2022	
11)	Toyoda H, Yasuda S, Shiota S, Sone Y, Maeda A, Kaneoka Y, Kumada T, <a href="#">Tanaka J</a>	Identification of the suitable candidates for EOB-MRI with the high risk of the presence of non-hypervascular hypointense nodules in patients with HCV infection	European Radiology	32(7)	5016-5023	2022	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
12)	Manry J, Bastard P, Gervais A, et al, <u>Tanaka J</u> (含む 180 人中 38 番 目)	The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodies	Proceedings of the National Academy of Sciences of the United States of America	119(21)	e220041 3119	2022	
13)	El-Ekiaby M, <u>Tanaka J</u> , van Drimmelen H, Allain JP, Lelie N	Infectivity of hepatitis B virus (HBV) surface antigen (HBsAg) positive plasma with undetectable HBV-DNA: Can HBsAg screening be discontinued in Egyptian blood donors?	Journal of Viral Hepatitis	29(5)	330-339	2022	○
14)	Sugiyama A, Kurisu A, Akita T, <u>Tanaka J</u>	Authors' response to "prevalence and incidence of fatty liver for people who took part in a health checkup in 2008-2019 in Japan"	Liver International	42(6)	1478	2022	○
15)	E B, Ou P, Ouoba S, Hussain Md RA, Ko K, Nagashima S, Sugiyama A, Akita T, <u>Tanaka J</u>	Prevalence and genotype distribution of viral hepatitis B in Cambodia between 1990 and 2020: A Systematic Review and Meta-analysis	Archives of Public Health	80(1)	119	2022	○
16)	Sugiyama A, Miwata K, Kitahara Y, Okimoto M, Abe K, Ouoba S, Akita T, Tanimine N, Ohdan H, Kubo T, Nagasawa A, Nakanishi T, Takafuta T, <u>Tanaka J</u>	Long COVID occurrence in COVID-19 survivors	Scientific Reports	12(1)	6039	2022	
17)	Sugiyama A, Kurisu A, E B, Ouoba S, Ko K, Rakhimov A, Akita T, Harakawa T, Sako T, Koshiyama M, Kumada T, <u>Tanaka J</u>	Distribution of FIB-4 index in the general population -Analysis of 75,666 residents who underwent health checkups-	BMC gastroenterology	22(1)	241	2022	○
18)	Toyoda H, Atsukawa M, Uojima H, Nozaki A, Takaguchi K, Hiraoka A, Itobayashi E, Watanabe T, Matsuura K, Shimada N, Abe H, Tsuji K, Itokawa N, Mikami S, Ishikawa T, Oikawa T, Yasuda S, Chuma M, <u>Tanaka J</u>	The Impact of cirrhosis and history of hepatocellular carcinoma on all-cause mortality after eradication of hepatitis C virus in patients with chronic hepatitis C	Gastro Hep Advances	1(4)	508	2022	○
19)	Kaneko S, Kurosaki M, Kurisu A, Akita T, <u>Tanaka J</u> , Kanto T	Impact of antiviral therapy for disease progression and non-invasive liver fibrosis index in patients with chronic hepatitis C: Markov chain model analysis	Hepatology Research	52(8)	665-676	2022	○
20)	Tada T, Kumada T, Matono T, Nakamura S, Sue M, Matuo Y, Masahiro T, Iijima H, <u>Tanaka J</u>	Characteristics of hepatocellular carcinoma in patients with hepatitis C virus who received direct-acting antiviral therapy and achieved sustained virological response: The impact of a hepatologist on surveillance	Journal of gastroenterology and hepatology open	6(7)	462-469	2022	○
21)	Ito M, Sugiyama A, Mino M, Kodama M, Nagaoki Y, Abe K, Imada H, Ouoba S, E B, Ko K, Akita T, Harakawa T, Sako T, Chayama K, <u>Tanaka J</u>	Prevalence of Helicobacter pylori infection in the general population evaluated by a resident-register-based epidemiological study	Journal of Gastroenterology	57(8)	540-546	2022	
22)	Kumada T, Toyoda H, Yasuda S, Ito T, Tsuji K, Fujioka S, Hiraoka A, Kariyama K, Nouso K, Ishikawa T, Tamai T, Tada T, <u>Tanaka J</u>	Factors linked to hepatocellular carcinoma development beyond 10 years after viral eradication in patients with hepatitis C virus	Journal of Viral Hepatitis	29(10)	919-929	2022	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
23)	<a href="#">Tanaka J</a> , Sun J	Special Issue:The Changing Epidemiology of Liver Disease in Asia	Liver International	42(9)	1926-2116	2022	○
24)	Sun J, <a href="#">Tanaka J</a> , Valenti L	The changing epidemiology of liver diseases in Asia	Liver International	42(9)	1926-1929	2022	○
25)	Sugiyama A, Kurisu A, Nagashima S, Hando K, Saipova K, Akhmedova S, Abe K, Imada H, Hussain Md RA, Ouoba S, E B, Ko K, Akita T, Yamazaki S, Yokozaki M, <a href="#">Tanaka J</a>	Seroepidemiological study of factors affecting anti-spike IgG antibody titers after a two-dose mRNA COVID-19 vaccination in 3744 healthy Japanese volunteers	Scientific Reports	12(1)	16294	2022	
26)	Hussain Md RA, Hiebert L, Sugiyama A, Ouoba S, Bunthen E, Ko K, Akita T, Kaneko S, Kanto T, Ward JW, <a href="#">Tanaka J</a>	Effect of COVID-19 on hepatitis B and C virus countermeasures: Hepatologist responses from nationwide survey in Japan	Hepatology Research	52(11)	899-907	2022	○
27)	Sugiyama A, Okada F, Abe K, Imada H, Ouoba S, E B, Hussain M RA, Ohisa M, Ko K, Nagashima S, Akita T, Yamazaki S, Yokozaki M, Kishita E, <a href="#">Tanaka J</a>	A longitudinal study of anti-SARS-CoV-2 antibody seroprevalence in a random sample of the general population in Hiroshima in 2020	Environmental Health and Preventive Medicine	27(0)	30	2022	
28)	Eto S, Nukui Y, Tsumura M, Nakagama Y, Kashimada K, Mizoguchi Y, Utsumi T, Taniguchi M, Sakura F, Noma K, Yoshida Y, Ohshimo S, Nagashima S, Okamoto K, Endo A, Imai K, Kanegane H, Ohnishi H, Hirata S, Sugiyama E, Shime N, Ito M, Ohge H, Kido Y, Bastard P, Casanova JL, Ohara O, <a href="#">Tanaka J</a> , Morio T, Okada S	Neutralizing type I interferon autoantibodies in Japanese patients with severe COVID-19	Journal of clinical immunology	42(7)	1360-1370	2022	
29)	Omori K, Shigemoto N, Kitagawa H, Nomura T, Kaiki Y, Miyaji K, Akita T, Kobayashi T, Hattori M, Hasunuma N, <a href="#">Tanaka J</a> , Ohge H	Virtual reality as a learning tool for improving infection control procedures	American journal of infection control	S0196-6553(22)	00465-5	2022	
30)	Okamoto Y, Hiyama T, Miyake Y, Yoshino A, Miyauchi S, <a href="#">Tanaka J</a>	Attitudes and behavior toward COVID-19 vaccination in Japanese university students: A cross-sectional study	Vaccines	10(6)	863	2022	
31)	Kumada T, Toyoda H, Yasuda S, Ogawa S, Gotoh T, Tada T, Ito T, Sumida Y, <a href="#">Tanaka J</a>	Combined ultrasound and magnetic resonance elastography predict hepatocellular carcinoma after hepatitis C virus eradication	Hepatology Research	52(11)	957-967	2022	○
32)	Kumada T, Toyoda H, Yasuda S, Ogawa S, Gotoh T, Ito T, Tada T, <a href="#">Tanaka J</a>	Liver stiffness measurements by 2D shear-wave elastography: Effect of steatosis on fibrosis evaluation	American journal of roentgenology	219(4)	604-612	2022	○
33)	Ishii S, Sugiyama A, Ito N, Miwata K, Kitahara Y, Okimoto M, Kurisu A, Abe K, Imada H, Akita T, Kubo T, Nagasawa A, Nakanishi T, Takafuta T, Kuwabara M, <a href="#">Tanaka J</a>	The role of discrimination in the relation between COVID-19 sequelae, psychological distress, and work impairment in COVID-19 survivors	Scientific reports	12(1)	22218	2022	
34)	Nagaoki Y, Sugiyama A, Mino M, Kodama H, Abe K, Imada H, Ouoba S, E B, Ko K, Akita T, Sako T, Kumada T, Chayama K, <a href="#">Tanaka J</a>	Prevalence of fatty liver and advanced fibrosis by ultrasonography and FibroScan in a general population random sample	Hepatology Research	52(11)	908-918	2022	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
35)	Kumada T, Ogawa S, Goto T, Toyoda H, Yasuda S, Ito T, Yasuda E, Akita T, <a href="#">Tanaka J</a>	Intra-individual comparisons of the ultrasound-guided attenuation parameter and the magnetic resonance imaging-based proton density fat fraction using bias and precision statistics	Ultrasound in Medicine and Biology	48(8)	1537-1546	2022	
36)	Toyoda H, Yasuda S, Moriya A, Itobayashi E, Uojima H, Watanabe T, Atsukawa M, Arai T, Ishikawa T, Mikami S, Hiraoka A, Tsuji K, Oikawa T, Tsubota A, Nozaki A, Chuma M, Abe H, Shima T, Kumada T, <a href="#">Tanaka J</a>	Misunderstanding of hepatitis C virus (HCV) infection status by non-specialized medical doctors in patients who achieved sustained virologic response to anti-HCV therapy	Journal of Infection and Chemotherapy	28(9)	1231-1234	2022	○
37)	児玉美穂、原鐵晃、頼英美、児玉尚志、大森百合子、秋田智之、 <a href="#">田中純子</a>	腹腔鏡下卵巣開孔術後の卵胞発育の有無は、術前 LH/FSH 比と卵巣単位体積当たり開孔数によって推測することができる Prediction of follicle development after laparoscopic ovarian drilling by the pre-operative LH/FSH ratio and number of drillings per ovarian unit volume.	日本産科婦人科内視鏡学会雑誌	38(1)	19-25	2022	
38)	<a href="#">田中純子</a>	わが国における肝臓の動向	肝がん白書		8-14	2022	○
39)	杉山文、栗栖あけみ、熊田卓、 <a href="#">田中純子</a>	大規模レセプトデータ解析による NASH 診断前生検実施割合の実態把握	肝臓	63(4)	211-213	2022	○
40)	Yokokawa H, Shinohara M, Teraoka Y, Imamura M, Nakamura N, Watanabe N, Date T, <a href="#">Aizaki H</a> , Iwamura T, Narumi H, Chayama K, Wakita T	Patient-derived monoclonal antibody neutralizes HCV infection in vitro and vivo without generating escape mutants.	PLoS One	17(9)		2022	
41)	Ando T, <a href="#">Aizaki H</a> , Sugiyama M, Date T, Hayashi K, Ishigami M, Katano Y, Goto H, Mizokami M, Muramatsu M, Kuroda M, Wakita T	Independent evolution of multi-dominant viral genome species observed in a hepatitis C virus carrier.	Biochem Biophys Rep	32		2022	
42)	Li X, Ito M, Aoyagi H, Murayama A, <a href="#">Aizaki H</a> , Fukasawa M, Kato T, Wakita T, Suzuki T	Development and Use of a Kinetic and Real-Time Monitoring System to Analyze the Replication of Hepatitis C Virus.	Int J Mol Sci	23(15)		2022	
43)	Kobayashi C, Watanabe Y, Oshima M, Hirose T, Yamasaki M, Iwamoto M, Iwatsuki M, Asami Y, Kuramochi K, Wakae K, <a href="#">Aizaki H</a> , Muramatsu M, Sureau C, Sunazuka T, Watashi K	Fungal Secondary Metabolite Exophillic Acid Selectively Inhibits the Entry of Hepatitis B and D Viruses.	Viruses	14(4)		2022	
44)	Yato K, Matsuda M, Watanabe N, Watashi K, <a href="#">Aizaki H</a> , Kato T, Tamura K, Wakita T, Muramatsu M, Suzuki R	Induction of neutralizing antibodies against hepatitis C virus by a subviral particle-based DNA vaccine.	Antiviral Res	199		2022	
45)	Norio Akuta, Hitomi Sezaki, Shunichiro Fujiyama, Yusuke Kawamura, <a href="#">Tetsuya Hosaka</a> , Mariko Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Yoshiyuki Suzuki, Fumitaka Suzuki, Hiromitsu Kumada	Simple Predictive Markers and Clinicopathological Features of Primary Liver Cancer following HCV Clearance with Direct-Acting Antivirals	Oncology			2023	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
46)	Suzuki H, Iwamoto H, Seki T, Nakamura T, Masuda A, Sakaue T, Tanaka T, Imamura Y, Niizeki T, Nakano M, Shimose S, Shirono T, Noda Y, Kamachi N, Sakai M, Morita K, Nakayama M, Yoshizumi T, Kuromatsu R, Yano H, Cao Y, <u>Koga H, Torimura T</u>	Tumor-derived insulin-like growth factor-binding protein-1 contributes to resistance of hepatocellular carcinoma to tyrosine kinase inhibitors.	Cancer Commun (Lond)	43(4)		2023	
47)	Shimose S, Hiraoka A, Casadei-Gardini A, Tsutsumi T, Nakano D, Iwamoto H, Tada F, Rimini M, Tanaka M, Torimura T, Suga H, Ohama H, Burgio V, Niizeki T, Moriyama E, Suzuki H, Shirono T, Noda Y, Kamachi N, Nakano M, Kuromatsu R, <u>Koga H, Kawaguchi T</u>	The beneficial impact of metabolic dysfunction-associated fatty liver disease on lenvatinib treatment in patients with non-viral hepatocellular carcinoma.	Hepatol Res	53(2)	104-115	2023	
48)	Iwamoto H, Niizeki T, Nagamatsu H, Ueshima K, Tani J, Kuzuya T, Kasai K, Kooka Y, Hiraoka A, Sugimoto R, Yonezawa T, Tanaka S, Deguchi A, Shimose S, Shirono T, Sakai M, Suzuki H, Moriyama E, <u>Koga H, Torimura T</u> , Kawaguchi T, New Fp Study Group, Kurume Liver Cancer Study Group Of Japan	The Clinical Impact of Hepatic Arterial Infusion Chemotherapy New-FP for Hepatocellular Carcinoma with Preserved Liver Function.	Cancers (Basel)	14(19)	4873	2022	
49)	Shimose S, Hiraoka A, Tanaka M, Iwamoto H, Tanaka T, Noguchi K, Aino H, Yamaguchi T, Itano S, Suga H, Niizeki T, Moriyama E, Shirono T, Noda Y, Kamachi N, Okamura S, Nakano M, Kawaguchi T, Kuromatsu R, <u>Koga H, Torimura T</u>	Deterioration of liver function and aging disturb sequential systemic therapy for unresectable hepatocellular carcinoma.	Sci Rep	12(1)	17018	2022	
50)	Shimose S, Hiraoka A, Casadei-Gardini A, Tsutsumi T, Nakano D, Iwamoto H, Tada F, Rimini M, Tanaka M, Torimura T, Suga H, Ohama H, Burgio V, Niizeki T, Moriyama E, Suzuki H, Shirono T, Noda Y, Kamachi N, Nakano M, Kuromatsu R, <u>Koga H, Kawaguchi T</u>	The beneficial impact of metabolic dysfunction-associated fatty liver disease on lenvatinib treatment in patients with non-viral hepatocellular carcinoma.	Hepatol Res	53(2)	104-115	2022	
51)	Tanaka T, Suzuki H, Miwa K, Ushijima T, Nagasu S, Fukahori M, Ishii K, Nakamura T, Iwamoto H, Masuda A, Sakaue T, <u>Koga H, Akagi Y, Murotani K, Torimura T</u>	Hyperlipidemia as a risk factor for Trousseau syndrome-related cerebral infarction in patients with advanced gastrointestinal cancer.	Oncol Lett	24(3)	318	2022	
52)	Shirono T, Iwamoto H, Niizeki T, Shimose S, Kajiwarra A, Suzuki H, Kamachi N, Noda Y, Okamura S, Nakano M, Kuromatsu R, Murotani K, <u>Koga H, Torimura T</u>	Durable complete response is achieved by balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. . 2022 Sep;.	Hepatol Commun	6(9)	2594-2604	2022	
53)	Arinaga-Hino T, Ide T, Akiba J, Suzuki H, Kuwahara R, Amano K, Kawaguchi T, Sano T, Inoue E, Koga H, Mitsuyama K, <u>Koga H, Torimura T</u>	Growth differentiation factor 15 as a novel diagnostic and therapeutic marker for autoimmune hepatitis.	Sci Rep	12(1)	8759	2022	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
54)	Suzuki H, Arinaga-Hino T, Sano T, Mihara Y, Kusano H, Mizuochi T, Togawa T, Ito S, Ide T, Kuwahara R, Amano K, Kawaguchi T, Yano H, Kage M, <a href="#">Koga H</a> , <a href="#">Torimura T</a>	Case Report: A Rare Case of Benign Recurrent Intrahepatic Cholestasis-Type 1 With a Novel Heterozygous Pathogenic Variant of ATP8B1.	Front Med (Lausanne)	9	891659	2022	
55)	Kuromatsu R, Ide T, Okamura S, Noda Y, Kamachi N, Nakano M, Shirono T, Shimose S, Iwamoto H, Kuwahara R, Arinaga-Hino T, Niizeki T, Zaizen Y, Takaki H, Shirachi M, <a href="#">Koga H</a> , <a href="#">Torimura T</a>	Hepatitis C Virus Elimination Using Direct Acting Antivirals after the Radical Cure of Hepatocellular Carcinoma Suppresses the Recurrence of the Cancer.	Cancers (Basel)	14(9)	2295	2022	
56)	Nakano D, Kawaguchi T, Tsutsumi T, Hayakawa M, Yoshio S, <a href="#">Koga H</a> , <a href="#">Torimura T</a>	Effects of SGLT2 inhibitor on tumor-releasing chemokines/cytokines in Hep3B and Huh7 cells.	JGH Open	6(4)	270-273	2022	
57)	Iwamoto H, Shimose S, Niizeki T, <a href="#">Koga H</a> , <a href="#">Torimura T</a>	Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma.	Clin Mol Hepatol	28(3)	575-579	2022	
58)	Suzuki H, Sano T, Shimasaki Y, Yamaguchi M, Ide T, Arinaga-Hino T, Kuwahara R, Amano K, Oshima K, Nagafuji K, Ida H, <a href="#">Koga H</a> , <a href="#">Torimura T</a>	TAFRO Syndrome That Responded to Prednisolone-only Treatment: Evaluating Changes in IL-6.	Intern Med	61(19)	2967-2972	2022	
59)	Suzuki H, Niizeki T, Shirono T, Koteda Y, Kinjyo Y, Mizukami N, Koda M, Ota S, Nakano M, Okamura S, Iwamoto H, Shimose S, Noda Y, Kamachi N, Kajiwara A, Suda K, Akiba J, Yano H, Kuromatsu R, <a href="#">Koga H</a> , <a href="#">Torimura T</a>	Robust Effect of Hepatic Arterial Infusion Chemotherapy and Radiation Therapy on Hepatocellular Carcinoma Arising from Fontan-associated Liver Disease.	Intern Med	61(8)	1145-1150	2022	
60)	Shirono T, <a href="#">Koga H</a> , Niizeki T, Nagamatsu H, Iwamoto H, Shimose S, Nakano M, Okamura S, Noda Y, Kamachi N, Kuromatsu R, Ogo E, <a href="#">Torimura T</a>	Usefulness of a novel transarterial chemoinfusion plus external-beam radiation therapy for advanced hepatocellular carcinoma with tumor thrombi in the inferior vena cava and right atrium: Case study.	Cancer Rep (Hoboken)	5(8)	e1539	2022	
61)	Lee CM, Yoon EL, Nakajima A, Yoneda M, <a href="#">Toyoda H</a> , Yasuda S, Lee J, Kim M, Kang BK, Nguyen MH, Jun DW, Sumida Y	A reappraisal of the diagnostic performance of B-mode ultrasonography for mild liver steatosis.	Am J Gastroenterol			in press	
62)	Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <a href="#">Toyoda H</a> , Ogawa C, Nishimura T, Shimada N, Kawata K, Kosaka H, Tanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano Y, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Kaibori K, Iijima H, Hiasa Y, Kumada T	Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non-viral infection: a Japanese multicenter observational study.	Cancer Med			in press	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
63)	Tada T, Kumada T, Hiraoka A, Kariyama K, Tani J, Hirooka M, Takaguchi K, Atsukawa M, Fukunishi S, Itobayashi E, Tsuji K, Tajiri K, Ochi H, Ishikawa T, Yasuda S, Ogawa K, <u>Toyoda H</u> , Hatanaka T, Nishimura T, Kakizaki S, Kawata K, Shimada N, Tada F, Nouse K, Tsutsui A, Ohama A, Morishita A, Nagano T, Itokawa N, Okubo T, Arai T, Kosaka H, Imai M, Naganuma A, Nakamura S, Koizumi Y, Kaibori M, Iijima H, Hiasa Y	New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a validation study.	Cancer Med			in press	
64)	Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Noritomo S, Kawata K, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y	Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab.	Cancer Med			in press	
65)	Ito T, Nguyen VH, Tanaka T, Park H, Yeh ML, Kawanaka M, Arai T, Atsukawa M, Yoon E, Tsai PC, <u>Toyoda H</u> , Huang JF, Henry L, Jun DW, Yu ML, Ishigami M, Nguyen MH, Cheung RC	Poor diagnostic efficacy of noninvasive tests for advanced fibrosis in obese or younger than 60 diabetic NAFLD patients.	Clin Gastroenterol Hepatol			in press	
66)	Seko Y, Takahashi H, <u>Toyoda H</u> , Hayashi H, Yamaguchi K, Iwaki M, Yoneda M, Arai T, Shima T, Fujii H, Morishita A, Kawata K, Tomita K, Kawanaka M, Yoshida Y, Ikegami T, Notsumata K, Oeda S, Kamada Y, Sumida Y, Fukushima H, Miyoshi E, Aishima S, Okanoue T, Nakajima A, Itoh Y, Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)	Diagnostic accuracy of enhanced liver fibrosis test for nonalcoholic steatohepatitis-related fibrosis: multicenter study.	Hepatol Res			in press	
67)	Fujii H, Fujii M, Iwaki M, Hayashi H, <u>Toyoda H</u> , Oeda S, Hyogo H, Kawanaka M, Morishita M, Munekage K, Kawata K, Tsutsumi T, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Kawada N, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T, Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)	A multicenter, retrospective, cohort study shows platelet counts predict HCC development in patients with NAFLD.	Hepatol Res			in press	



	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
68)	Persano M, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Rimassa L, Presa J, Masi G, Yoo C, Lonardi S, Tovoli F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Pressiani T, Kawaguchi T, Montes M, Vivaldi C, Solda C, Piscaglia F, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Iavarone M, Di Costanzo G, Marra F, Scartozzi M, Tamburini E, Cabibbo G, Foschi FG, Silletta M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Cammarota A, Burgio V, Cascinu S, Casadei-Gardini A	Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study.	J Cancer Res Clin Oncol			in press	
69)	Rimini M, Persano M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Presa J, Salani F, Lonardi S, Piscaglia F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Schirripa M, Montes M, Vivaldi C, Solda C, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Burgio V, Scartozzi M, Cascinu S, Casadei-Gardini A	Survival outcomes from atezolizumab plus bevacizumab versus lenvatinib versus sorafenib in Child Pugh B unresectable hepatocellular carcinoma patients.	J Cancer Res Clin Oncol			in press	
70)	Yamauchi R, Ito T, Yoshio S, Yamamoto T, Mizuno K, Ishigami M, Kawashima H, Yasuda S, Shimose S, Iwaomto H, Yamazoe T, Mori T, Kakazu E, Kawaguchi T, <u>Toyoda H</u> , Kanto T	Serum osteopontin as a predictive biomarker for the response to atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma.	J Gastroenterol			in press	

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
71) Ishiba H, Sumida Y, Kamada Y, Fujii, MD H, Iwaki M, Hayashi H, <u>Toyoda H</u> , Oeda S, Hyogo H, Kawanaka M, Morishita A, Munekage K, Kawata K, Tsutsumi T, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Takahashi H, Ueda S, Aishima S, Nakajima A, Okanoue T, Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)	Noninvasive tests predict liver-related events and mortality in patients with non-alcoholic fatty liver disease: sub-analysis of the CLIONE-Asia study.	J Gastroenterol Hepatol			in press	
72) Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kaibori M, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Kosaka H, Hiasa Y, Kudo M	Relationship of atezolizumab plus bevacizumab treatment with muscle volume loss in unresectable hepatocellular carcinoma patients- multicenter analysis.	Liver Cancer			in press	
73) Hiraoka A, Kumada T, Tada T, <u>Toyoda H</u> , Kariyama K, Hatanaka T, Kakizaki S, Naganuma A, Itobayashi E, Tsuji K, Ishikawa T, Ohama H, Tada F, Nouso K	Attempt to establish prognostic predictive system for hepatocellular carcinoma using artificial intelligence for assistance with selection of treatment modality.	Liver Cancer			in press	
74) <u>Toyoda H</u>	Low surveillance receipt in cirrhotic patients with cured HCV: where are the barriers?	Liver Int			in press	○
75) Tada T, Kumada T, Hiraoka A, Kariyama K, Tani J, Hirooka M, Takaguchi K, Atsukawa M, Fukunishi S, Itobayashi E, Tsuji K, Tajiri K, Ochi H, Ishikawa T, Yasuda S, Ogawa C, <u>Toyoda H</u> , Hatanaka T, Nishimura T, Kakizaki S, Kawata K, Shimada N, Tada F, Nouso K, Tsutsui A, Ohama H, Morishita A, Nagano T, Itokawa N, Okubo T, Arai T, Kosaka H, Imai M, Naganuma A, Nakamura S, Koizumi Y, Matono T, Kaibori M, Iijima H, Hiasa Y	Nutritional status is associated with prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab.	Oncology			in press	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
76)	Persano M, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Yoo C, Lonardi S, Stefanini B, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Montes M, Vivaldi C, Solda C, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Burgio V, Della Corte A, Ratti F, De Cobelli F, Aldrighetti L, Scartozzi M, Cascinu S, Casadei-Gardini A	Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab.	Oncology			in press	
77)	Ohama H, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Matono T, Shibata H, Aoki T, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y, Kudo M, Kumada T	Comparison between atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma in patients with Child-Pugh class B in real-world clinical settings.	Oncology			in press	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
78)	Rimini M, Persano M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Yoo C, Lonardi S, Piscaglia F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Pressiani T, Montes M, Vivaldi C, Solda C, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Burgio V, Rimassa L, Scartozzi M, Cascinu S, Casadei-Gardini A	Real-world data for atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: how does adherence to the IMbrave150 trial inclusion criteria impact prognosis?	Target Oncol			in press	
79)	<u>Toyoda H</u> , Kariyama K, Hiraoka A	Rising incidence and poor survival in patients with nonviral HCC – better HCC surveillance and treatment for alcohol-associated and non-alcohol fatty liver diseases are needed. authors' reply.	Aliment Pharmacol Ther	57	363-364	2023	
80)	Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Shibata H, Aoki T, Tanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Kaibori M, Hiasa Y, Kudo M	Does first-line treatment have prognostic impact for unresectable HCC? –atezolizumab plus bevacizumab vs. lenvatinib.	Cancer Med	12	325-334	2023	
81)	Hatanaka T, Kakizaki S, Hiraoka A, Kariyama K, Tsuji K, Ishikawa T, <u>Toyoda H</u> , Yasuda S, Naganuma A, T Tada, Takaguchi K, Tsutsui A, Itobayashi E, Shimada N, Shibata H, Tanaka T, Nagano T, Imai M, Nakamura S, Nouse K, Kosaka H, Kaibori M, Kumada T	The prognosis of elderly patients with hepatocellular carcinoma: a multi-center 19-year experience in Japan.	Cancer Med	12	345-357	2023	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
82)	Hatanaka T, Naganuma A, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Shimada N, Kawata K, Kosaka H, Kakizaki S, Tanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa H, Kumada T	The hepatocellular carcinoma modified Gustave Roussy Immune Score (HCC-GRIm-Score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: a multicenter retrospective analysis.	Cancer Med	12	4259-4269	2023	
83)	Fujii H, Iwaki M, Hayashi H, <u>Toyoda H</u> , Oeda S, Hyogo H, Kawanaka M, Morishita A, Munekage K, Kawata K, Yamamura S, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Kawada N, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T, Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)	Clinical outcomes in biopsy-proven nonalcoholic fatty liver disease patients: a multicenter registry-based cohort study.	Clin Gastroenterol Hepatol	21	370-379	2023	
84)	Casadei-Gardini A, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Rimassa L, Presa J, Masi G, Yoo C, Lonardi S, Tovoli F, Kumada K, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Pressiani T, Montes M, Vivaldi C, Solda C, Piscaglia F, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Iavarone M, Di Costanzo G, Marra F, Scartozzi M, Tamburini E, Cabibbo G, Foschi FG, Silletta M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Burgio V, Persano M, Della Corte A, Ratti F, De Cobelli F, Aldrighetti L, Cascinu S, Cucchetti A	Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real life worldwide population.	Eur J Cancer	180	9-20	2023	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
85)	Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Shimada N, Kawata K, Kosaka H, Tanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kumada T	Development and validation of a modified albumin-bilirubin grade and $\alpha$ -fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab.	Hepato Int	17	86-96	2023	
86)	Atsukawa M, Tsubota A, Kondo C, Shioda-Koyano K, Ishikawa T, <u>Toyoda H</u> , Takaguchi K, Watanabe T, Matsuura K, Ogawa C, Hiraoka A, Okubo H, Tateyama M, Uojima H, Nozaki A, Chuma M, Kato K, Mikami S, Tani J, Morishita A, Kawata K, Tada T, Furuichi Y, Okubo T, Kawano T, Arai T, Kawabe N, Kawamura N, Ikegami T, Nakamuta M, Iwasa M, Tanaka Y, Hatano M, Iwakiri K	Risk factors for portopulmonary hypertension in patients with cirrhosis: a prospective multicenter study.	Hepato Int	17	139-149	2023	
87)	Hayama K, Atsukawa M, Tsubota A, Kondo C, Iwasa M, Hasegawa H, Takaguchi K, Tsutsui A, Uojima H, Hidaka H, Okubo H, Suzuki T, Matsuura K, Tada T, Kawabe N, Tani J, Morishita A, Ishikawa T, Arase Y, Furuichi Y, Kato K, Kawata K, Chuma M, Nozaki A, Hiraoka A, Watanabe T, Kagawa T, <u>Toyoda H</u> , Tani N, Yoshida H, Tanaka Y, Iwakiri K	Clinical outcomes of antithrombin III-based therapy for patients with portal vein thrombosis: a retrospective, multicenter study.	Hepato Res	53	51-60	2023	
88)	Watanabe M, <u>Toyoda H</u> , Kawabata T	Rapid quantification assay of hepatitis B virus DNA in human serum and plasma by fully automated genetic analyzer $\mu$ TAS Wako g1.	PLoS ONE	18	e0278143	2023	
89)	Oeda S, Seko Y, Hayashi H, Arai T, Iwaki M, Yoneda M, Shima T, Notsumata K, Ikegami T, Fujii H, <u>Toyoda H</u> , Miura K, Morishita A, Kawata K, Tomita K, Kawanaka M, Isoda H, Yamaguchi K, Fukushima H, Kamada Y, Sumida Y, Aishima S, Itoh Y, Okanoue T, Nakajima A, Takahashi H, Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)	Validation of the utility of Agile scores to identify advanced fibrosis and cirrhosis in Japanese patients with nonalcoholic fatty liver disease.				2023	
90)	<u>Toyoda H</u> , Kariyama K, Hiraoka A, Tsuji K, Ishikawa T, Hatanaka T, Naganuma A, Yasuda S, Nouse K, Kakizaki S, Kumada T, Innes H, Johnson PJ	Improved survival of viral HCC but non-viral HCC from 2000 to 2020: a multicenter cohort study of 6,007 patients from high-volume academic centers in Japan.	Aliment Pharmacol Ther	56	694-701	2022	
91)	<u>Toyoda H</u> , Kariyama K, Hiraoka A	Non-viral hepatocellular carcinoma surveillance – an increasingly severe public health issue. – authors' reply.	Aliment Pharmacol Ther	56	750-751	2022	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
92)	Kumada T, <u>Toyoda H</u> , Yasuda S, Ogawa S, Gotoh T, Ito T, Tada T, Tanaka J	Liver stiffness measurements by 2D shear-wave elastography: effect of steatosis on fibrosis evaluation.	Am J Roentogenol	219	604-612	2022	
93)	Matsushima-Nishiwaki R, <u>Toyoda H</u> , Maeda A, Kaneoka Y, Kumada T, Kozawa O	Correlation between the complex of small heat shock proteins (HSPBs) and the progression in patients with hepatocellular carcinoma.	Arch Biochem Biophys	732	109461	2022	
94)	Johnson PJ, Innes H, Hughes DM, Kalyuzhnyy A, Kumada T, <u>Toyoda H</u>	Evaluation of the aMAP score for hepatocellular carcinoma surveillance: a realistic opportunity to risk stratify.	Br J Cancer	127	1263-1269	2022	
95)	Yamamoto T, Ito T, Hase, T, Ishigami, M, Mizuno K, Yamamoto K, Imai N, Ishizu Y, Honda T, Shibata H, Hatta T, Yogo N, Yasuda S, <u>Toyoda H</u> , Abe T, Kawashima H, Hashimoto N, Fujishiro M	Immune-related liver injury is a poor prognostic factor in patients with non-small cell lung cancer treated with immune checkpoint inhibitors.	Cancer Invest	40	189-198	2022	
96)	Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y	Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: a multicenter analysis.	Cancer Med	11	3796-3808	2022	
97)	Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, Kudo M	Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: early clinical experience.	Cancer Rep	5	e1464	2022	
98)	Park J, Le AK, Tseng TC, Yeh ML, Jun DW, Trinh H, Wong GLH, Chen CH, Peng CY, Kim SE, Oh H, Kwak MS, Cheung KS, <u>Toyoda H</u> , Hsu YC, Jeong JY, Yoon EL, Ungtrakul T, Zhang J, Xie Q, Ahn SB, Enomoto M, Shim JJ, Cunningham C, Jeong SW, Cho YK, Ogawa E, Huang R, Lee DH, Takahashi H, Tsai PC, Huang CF, Dai CY, Tseng CH, Yasuda S, Kozuka R, Li J, Wong C, Wong CC, Zhao C, Hoang J, Eguchi Y, Wu C, Tanaka Y, Gane E, Tanwandee T, Cheung R, Yuen MF, Lee HS, Yu ML, Kao JH, Yang HI, Nguyen MH	Progression rates by age, sex, treatment, and disease activity by AASLD and EASL criteria: data for precision medicine..	Clin Gastroenterol Hepatol	20	874-885	2022	

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
99) Imajo K, <u>Toyoda H</u> , Yasuda S, Suzuki Y, Sugimoto K, Kuroda H, Yasui Y, Kurosaki M, Izumi N, Nakajima A, Kumada T	Utility of ultrasound-guided attenuation parameter for the quantification of steatosis with reference to MRI-based proton density fat fraction: a multicenter, prospective study.	Clin Gastroenterol Hepatol	20	2533-2541	2022	
100) Tada T, Kumada T, <u>Toyoda H</u> , Nakamura S, Endo Y, Kaneoka Y, Hiraoka A, Joko K, Hirooka M, Hiasa Y	A validation study of combined resection and ablation therapy for multiple hepatocellular carcinoma.	Clin Radiol	77	114-120	2022	
101) Chuma M, Yokoo H, Hiraoka A, Ueda K, Yokoyama T, Tsuji K, Shimada N, Uojima H, Kobayashi S, Hattori N, Okubo T, Atsukawa M, Ishikawa T, Takaguchi K, Tsutsui A, <u>Toyoda H</u> , Tada T, Saito Y, Hirose S, Tanaka T, Takeda K, Otani M, Sekikawa Z, Watanabe T, Hidaka H, Morimoto M, Numata K, Kagawa T, Sakamoto M, Kumada T, Maeda S	Identification of CT values that could be predictive of necrosis (N-CTav) in hepatocellular carcinoma after lenvatinib treatment.	Curr Oncol	29	3259-3271	2022	
102) Kam LY, Huang DQ, Teng MLP, Takahashi H, Tanaka K, Yasuda S, Fung J, Lee TY, Hyogo H, Ono M, Saruwatari J, Oniki K, Yeo YH, Barnett S, Henry L, Li J, Zou B, Cheung RC, Kumada T, Yuen MF, Eguchi Y, <u>Toyoda H</u> , Nguyen MH	Clinical profiles of Asians with NAFLD: a systematic review and meta-analysis.	Dig Dis	40	734-744	2022	
103) Rimini M, Rimassa L, Ueshima K, Burgio V, Shimose S, Tada T, Suda G, Yoo C, Cheon J, Pinato DJ, Lonardi S, Scartozzi M, Iavarone M, Di Costanzo GG, Marra F, Solda C, Tamburini E, Piscaglia F, Masi G, Cabibbo G, Foschi FG, Silletta M, Pressiani T, Nishida N, Iwamoto H, Sakamoto N, Ryoo BY, Chon HJ, Claudia F, Niizeki T, Sho T, Kang B, Antonio D, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimur T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, Pedica F, De Cobelli F, Ratti F, Alighetti L, Kudo M, Cascinu S, Casadei-Gardini A	Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis.	ESMO Open	7	100591	2022	



	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
104)	Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y	Neutrophil-lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis.	Eur J Gastroenterol Hepatol	34	698-706	2022	
105)	<u>Toyoda H</u> , Yasuda S, Shiota S, Kumada T, Tanaka J	Adherence to regular surveillance visits for HCC in patients with chronic hepatitis C virus infection who achieved sustained virologic response.	Eur J Gastroenterol Hepatol	34	693-697	2022	○
106)	Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Aoki T, Koizumi Y, Nakamura S, Joko K, Hiasa Y, Kudo M	Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysis.	Eur J Gastroenterol Hepatol	34	857-864	2022	
107)	<u>Toyoda H</u> , Yasuda S, Shiota S, Sone Y, Maeda A, Kaneoka Y, Kumada T, Tanaka J	Identification of the suitable candidates for EOB-MRI with the high risk of the presence of non-hypervascular hypointense nodules in patients with HCV infection.	Eur Radiol	32	5016-5023	2022	○
108)	<u>Toyoda H</u> , Atsukawa M, Uojima H, Nozaki A, Takaguchi K, Hiraoka A, Itobayashi E, Watanabe T, Matsuura K, Shimada N, Abe H, Tsuji K, Itokawa N, Mikami S, Ishikawa T, Oikawa T, Yasuda S, Chuma M, Tsutsui A, Ikeda H, Arai T, Tsubota A, Kumada T, Tanaka Y, Tanaka J	The impact of cirrhosis and history of HCC on all-cause mortality after eradication of HCV in patients with chronic hepatitis C.	Gastro Hep Adv	1	508-515	2022	○
109)	Kariyama K, Kawanaka M, Nouso K, Hiraoka A, <u>Toyoda H</u> , Tada T, Ishikawa T, Wakuta A, Miyake N, Murakami S, Shiota S, Kumada T	Fibrosis-3 index: a new score to predict liver fibrosis in patients with nonalcoholic fatty liver disease without age as a factor.	Gastro Hep Adv	1	1108-1113	2022	
110)	Korenaga M, Murata K, Izumi N, Tamaki N, Yokosuka O, Takehara T, Sakamoto N, Suda G, Nishiguchi S, Enomoto H, Ikeda F, Yanase M, <u>Toyoda H</u> , Genda T, Umemura T, Yatsuhashi H, Yamasaki K, Ide T, Toda N, Kanda T, Nirei K, Ueno Y, Haga H, Nishigaki Y, Nakane K, Omata M, Mochizuki H, Aoki Y, Imamura M, Kanto T, Mizokami M	No increased risk of hepatocellular carcinoma after eradication of hepatitis C virus by direct-acting antivirals, compared with interferon-based therapy.	Global Health Med	4	216-224	2022	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
111)	Sapena V, Enea M, Torres F, Celsa C, Rios J, Rizzo GEM, Nahon P, Marino Z, Tateishi R, Minami T, Sangiovanni A, Fornis X, <u>Toyoda H</u> , Brillanti S, Conti F, Degaspero E, Yu ML, Tsai PC, Jean K, El Kassas M, Shousha HI, Abdelaziz AO, Zavaglia C, Nagata H, Nakagawa M, Asahina Y, Singal AG, Murphy CC, Kohla M, Masetti C, Dufour JF, Merchante N, Cavalletto L, Chemello L, Pol S, Crespo J, Calleja JL, Villani R, Serviddio G, Zanetto A, Shalaby S, Russo FP, Bielen R, Trevisani F, Camma C, Bruix J, Cabibbo G, Reig M	Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis.	Gut	71	593-604	2022	○
112)	Tamaki N, Kurosaki M, Yasui Y, Mori N, Tsuji K, Hasebe C, Joko K, Akahane T, Furuta K, Kobashi H, Kimura H, Yagisawa H, Marusawa H, Kondo M, Kojima Y, Yoshida H, Uchida Y, Tada T, Nakamura S, Yasuda S, <u>Toyoda H</u> , Loomba R, Izumi N	Hepatocellular carcinoma risk assessment for patients with advanced fibrosis after eradication of hepatitis C virus.	Hepatology Commun	6	461-472	2022	○
113)	Reveron-Thornton RF, Teng MLP, Lee EY, Tran A, Vajanaphanich S, Tan EX, Nerurkar SN, Ng RX, Teh R, Tripathy DP, Ito T, Tanaka T, Miyake N, Zou B, Wong C, <u>Toyoda H</u> , Esquivel CO, Bonham CA, Nguyen MH, Huang DQ	Global and regional long-term survival following resection for HCC in the recent decade: a meta-analysis of 110 studies.	Hepatology Commun	6	1813-1826	2022	
114)	Kawata K, Atsukawa M, Ohta K, Chida T, Noritake H, Arai T, Iwakiri K, Yasuda S, <u>Toyoda H</u> , Okubo T, Hiraoka A, Watanabe T, Uojima H, Nozaki A, Tani J, Morishita A, Kageyama F, Sasada Y, Nagasawa M, Matsushita M, Oyaizu T, Mikami S, Ikegami T, Abe H, Matsuura K, Tanaka Y, Tsubota A	Mac-2-binding protein glycan isomer predicts all malignancies post-sustained virological response in chronic hepatitis C.	Hepatology Commun	6	1855-1869	2022	○
115)	<u>Toyoda H</u> , Atsukawa M	The best predictive model for post-SVR HCC: can it be universal?	Hepatology Int	16	728	2022	○
116)	Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Shimada N, Kawata K, Kosaka H, Tanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Kaibori M, Iijima H, Hiasa Y, Kumada T	Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study.	Hepatology Int	16	1150-1160	2022	

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
117) Hsu YC, Jun DW, Peng CY, Yeh ML, Trinh H, Wong GL, Kim SE, Chen CH, Oh H, Lin CH, Trinh L, Wong VW, Yoon E, Ahn SB, Huang D, Cho YK, Jeong JY, Jeong SW, Kim HS, Xie Q, Liu L, Riveiro-Barciela M, Tsai PC, Accarino EV, <a href="#">Toyoda H</a> , Enomoto M, Preda C, Marciano S, Hoang J, Huang CF, Kozuka R, Yasuda S, Istratescu D, Lee DH, Su JY, Huang YT, Huang JF, Dai CY, Chuang WL, Yuen MF, Gadano A, Cheung R, Lim SG, Buti M, Yu ML, Nguyen MH	Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort.	Hepato Int	16	1297-1307	2022	
118) <a href="#">Toyoda H</a> , Yasuda S, Shiota S, Kumada T	Long-term persistence of hepatocarcinogenic potential of a non-hypervascular hypointense nodule on EOB-MRI after the eradication of hepatitis C virus.	Hepato Res	52	128-132	2022	○
119) Kumada T, <a href="#">Toyoda H</a> , Yasuda S, Ito T, Tanaka J	Mortality of inactive hepatitis B virus carriers in Japan is similar to that of the general population.	Hepato Res	52	81-92	2022	
120) Shiha G, Soliman R, Mikhail NNH, Alswat K, Abdo AA, Sanai FM, Derbala MFM, Ormeci N, Dalekos GN, Al-Busafi SA, Hamoudi W, Sharara AI, Zaky S, El-Raey F, Mabrouk MS, Marzouk SY, <a href="#">Toyoda H</a>	Development and multicenter validation of FIB-6; a novel, machine-learning, simple bedside score to rule out liver cirrhosis and compensated advanced chronic liver disease in CHC patients.	Hepato Res	52	165-175	2022	○
121) Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <a href="#">Toyoda H</a> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Tanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, Kudo M	Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to 7 criteria –multicenter analysis.	Hepato Res	52	308-316	2022	
122) Atsukawa M, Tsubota A, Kondo C, <a href="#">Toyoda H</a> , Nakamuta M, Takaguchi K, Watanabe T, Hiraoka A, Uojima H, Ishikawa T, Iwasa M, Tada T, Nozaki A, Chuma M, Fukunishi S, Asano T, Ogawa C, Abe H, Kato K, Hotta N, Shima T, Matsuura K, Mikami S, Tachi Y, Fujioka S, Okubo H, Shimada N, Tani J, Morishita A, Hidaka I, Moriya A, Tsuji K, Akahane T, Okubo T, Arai T, Kitamura M, Morita K, Kawata K, Tanaka Y, Kumada T, Iwakiri K, KTK49 Liver Study Group	Time-course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis.	Hepato Res	52	235-246	2022	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
123)	Hatanaka T, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <a href="#">Toyoda H</a> , Ogawa C, Nishimura T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, Kumada T	Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a landmark analysis.	Hepatol Res	52	462-470	2022	
124)	Tanaka T, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <a href="#">Toyoda H</a> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Kaibori M, Hiasa Y, Kudo M, Kumada T	Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice.	Hepatol Res	52	773-783	2022	
125)	Kumada T, <a href="#">Toyoda H</a> , Yasuda S, Ogawa S, Gotoh T, Tada T, Ito T, Sumida Y, Tanaka J	Combined ultrasound and magnetic resonance elastography predict hepatocellular carcinoma after hepatitis C virus eradication.	Hepatol Res	52	957-967	2022	○
126)	Rimini M, Kang W, Burgio V, Persano M, Aoki T, Shimose S, Tada T, Kumada T, Sho T, Lai E, Celsa C, Campani C, Tonnini M, Tamburini E, Hiraoka A, Takaguchi K, Nishida N, Iwamoto H, Itobayashi E, Tsuji K, Sakamoto N, Ishikawa T, <a href="#">Toyoda H</a> , Kudo M, Kawaguchi T, Hatanaka T, Nouse K, Suda G, Cabibbo G, Marra F, Della Corte A, Ratti F, Pedica F, De Cobellii F, Aldrighetti L, Scartozzi M, Cascinu S, Casadei Gardini A	Validation of the easy-to-use lenvatinib prognostic (LEP) index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib.	Hepatol Res	52	1050-1059	2022	
127)	<a href="#">Toyoda H</a>	Sofosbuvir/velpatasvir and glecaprevir/pibrentasvir: how should we choose among these two last regimens?	Hepatol Res	52	815-816	2022	○
128)	Kawamura N, Imajo K, Kalutkiewicz KJ, Nagai K, Iwaki M, Kobayashi T, Nogami A, Honda Y, Kessoku T, Ogawa Y, Higurashi T, Hosono K, Takahashi H, Yoneda M, Saito S, Aishima S, <a href="#">Toyoda H</a> , Hayashi H, Sumida Y, Ehman RL, Nakajima A	Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease.	Hepatology	76	186-195	2022	
129)	Johnson P, Pinato DJ, Kalyuzhnyy A, <a href="#">Toyoda H</a>	Breaking the Child-Pugh dogma in hepatocellular carcinoma.	J Clin Oncol	40	2078-2082	2022	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
130)	Nishida N, Yamakawa M, Shiina T, Mekada Y, Nishida M, Sakamoto N, Nishimura T, Iijima H, Hirai T, Takahashi K, Sato M, Tateishi R, Ogawa M, Mori H, Kitano M, <u>Toyoda H</u> , Ogawa C, Kudo M, JSUM AI investigators	Development of artificial intelligence (AI) for the ultrasonographic diagnosis of liver tumor and comparison of diagnostic accuracy with AI versus human experts.	J Gastroenterol	57	309-321	2022	
131)	Kariyama K, Hiraoka A, Kumada T, Yasuda S, <u>Toyoda H</u> , Tsuji K, Hatanaka T, Kakizaki S, Naganuma A, Tada T, Takaguchi K, Itobayashi E, Ishikawa T, Shimada N, Tsutsui A, Nagano T, Imai M, Nakamura S, Wakuta A, Miyake N, Shiota S, Nouse K	Chronological change in serum albumin as a good prognostic factor in patients with hepatocellular carcinoma treated with lenvatinib: proposal of albumin simplified grading based on the modified albumin-bilirubin score (ALBS grade).	J Gastroenterol	57	581-586	2022	
132)	Sakamoto K, Ito K, Yotsuyanagi H, Yatsuhashi H, Tanaka Y, Hige S, Takikawa Y, Ueno Y, Yamamoto K, Imazeki F, Inoue J, Kurosaki M, Umemura T, <u>Toyoda H</u> , Mita E, Michitaka K, Maeshiro T, Yamada N, Suetsugu A, Kawanaka M, Seko Y, Matsuura K, Okumura A, Fukuzawa Y, Sugiyama M, Mizokami M, Yoneda M	Trends of hepatitis B virus genotype distribution in chronic hepatitis B patients in Japan.	J Gastroenterol	57	971-980	2022	
133)	Seko Y, Kawanaka M, Fujii H, Iwaki M, Hayashi H, <u>Toyoda H</u> , Oeda S, Hyogo H, Morishita A, Munekage K, Kawata K, Yamamura S, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Okanoue T, Itoh Y, Nakajima A	Age-dependent effects of diabetes and obesity on liver-related events in nonalcoholic fatty liver disease: subanalysis of CLIONE in Asia.	J Gastroenterol Hepatol	37	2313-2320	2022	
134)	<u>Toyoda H</u> , Yasuda S, Moriya A, Itobayashi E, Uojima H, Watanabe T, Atsukawa M, Arai T, Ishikawa T, Mikami S, Hiraoka A, Tsuji K, Oikawa T, Tsubota A, Nozaki A, Chuma M, Abe H, Shima T, Kumada T, Tanaka J	Misunderstanding of hepatitis C virus (HCV) infection status by non-specialized medical doctors in patients who achieved sustained virologic response to anti-HCV therapy.	J Infect Chemother	28	1231-1234	2022	○
135)	Shiha G, Soliman R, Mikhail NNH, Carrat F, Azzi J, Ganne-Carrie N, <u>Toyoda H</u> , Uojima H, Nozaki A, Takaguchi K, Hiraoka A, Atsukawa M, Abe H, Matsuura K, Mikami S, Watanabe T, Tsuji K, Ishikawa T, Suri V, Osinusi A, Ni L, Zou J, Sarin S, Kumar M, Jalal PK, Hashim MA, Hassan M, Lopez SA, Banares R, Ahumada AM, Mousa N, Eslam M, Waked I	International multicenter validation of GES score for HCC risk stratification in chronic hepatitis C patients.	J Viral Hepat	29	807-816	2022	○
136)	Kumada T, <u>Toyoda H</u> , Yasuda S, Ito T, Tsuji K, Fujioka S, Hiraoka A, Kariyama K, Nouse K, Ishikawa T, Tamai T, Tada T, Tanaka J	Factors linked to hepatocellular carcinoma development beyond 10 years after viral eradication in patients with hepatitis C virus.	J Viral Hepat	29	919-929	2022	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
137)	<a href="#">Toyoda H</a> , Johnson PJ	The ALBI score: from liver function in patients with HCC to a general measure of liver function.	JHEP Rep	4(10)	100557	2022	
138)	Casadei-Gardini A, Rimini M, Kudo M, Shimose S, Tada T, Suda G, Goh MJ, Jefremow A, Scartozzi M, Cabibbo G, Campani C, Tamburini E, Tovoli F, Ueshima K, Aoki T, Iwamoto H, Torimura T, Kumada T, Hiraoka A, Atsukawa M, Itobayashi E, <a href="#">Toyoda H</a> , Sakamoto N, Sho T, Kang W, Siebler J, Neurath MF, Burgio V, Cascinu S	REal life study of LEnVAtiNib therapy for HepAtocellular carcinoma: RELEVANT study.	Liver Cancer	11	527-539	2022	
139)	Hiraoka A, Kumada T, Kariyama K, <a href="#">Toyoda H</a> , Yasuda S, Tsuji K, Hatanaka T, Kakizaki S, Naganuma A, Ishikawa T, Tada T, Takaguchi K, Itobayashi E, Shimada N, Tanaka T, Tsutsui A, Nagano T, Imai M, Nakamura S, Nouse K, Shibata H	Simple scoring system for predicting TACE unsuitable among intermediate stage hepatocellular carcinoma patients in multiple systemic treatment era.	Oncology	100	65-73	2022	
140)	Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <a href="#">Toyoda H</a> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Ohama H, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y, Kudo M	Clinical predictor of urinary protein as adverse event associated with atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma.	Oncology	100	645-654	2022	
141)	Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <a href="#">Toyoda H</a> , Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Aoki T, Koizumi Y, Nakamura S, Joko K, Hiasa Y, Kudo M	C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysis.	Sci Rep	12(1)	8421	2022	
142)	Kawano T, Atsukawa M, Tsubota A, Shimada N, <a href="#">Toyoda H</a> , Takaguchi K, Tani J, Morishita A, Hiraoka A, Mikami S, Ishikawa T, Okubo H, Watanabe T, Okubo T, Arai T, Hayama K, Itokawa N, Kondo C, Iwakiri K	Shorter pruritus period and milder disease stage are associated with response to nalfurafine hydrochloride in patients with chronic liver disease.	Sci Rep	12	7311	2022	
143)	Kumada T, Ogawa S, Goto T, <a href="#">Toyoda H</a> , Yasuda S, Ito T, Yasuda E, Akita T, Tanaka J	Intra-individual comparisons of the ultrasound-guided attenuation parameter and magnetic resonance imaging-based proton density fat fraction using bias and precision statistics.	Ultrasound Med Biol	48	1537-1546	2022	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
144)	Endo K, Kakisaka K, Kuroda H, <u>Miyasaka A</u> , Takikawa Y, Matsumoto T	Annual changes in grip strength and skeletal muscle mass in chronic liver disease: observational study.	Sci Rep	13	1648.doi : 10.1038 /s41598 -023- 28528- w.	2023	
145)	Endo K, Sato T, Yoshida Y, Kakisaka K, <u>Miyasaka A</u> , Takikawa Y	Viral eradication by direct-acting antivirals does not decrease the serum myostatin level in patients infected with hepatitis C.	Nutrition	101	111699. doi: 10.1016 /j.nut.20 22.1116 99.	2022	
146)	Kakisaka K, Sato T, Wada Y, Ito A, Eto H, Abe H, Kanazawa J, Yusa K, Endo K, Yoshida Y, Oikawa T, Kuroda H, <u>Miyasaka A</u> , Akasaka M, Matsumoto T	Lactulose: A treatment for hyperammonemia in a lysinuric protein-intolerant patient with dynamic blood amino acid concentrations.	Mol Genet Metab Rep	32	100898. doi: 10.1016 /j.ymgm r.2022.1 00898	2022	
147)	<u>Shimakami T</u> , Setoyama H, Oza N, Itakura J, Kaneko S, Korenaga M, Toyama T, Tanaka J, Kanto T	Development of performance indicators for hepatitis countermeasures as a tool for the assessment and promotion of liver cancer prevention in Japan.	J Gastroenterol			2023	○
148)	Li YY, Kuroki K, <u>Shimakami T</u> , Murai K, Kawaguchi K, Shirasaki T, Nio K, Sugimoto S, Nishikawa T, Okada H, Orita N, Takayama H, Wang Y, Thi Bich PD, Ishida A, Iwabuchi S, Hashimoto S, Shimaoka T, Tabata N, Watanabe-Takahashi M, Nishikawa K, Yanagawa H, Seiki M, Matsushima K, Yamashita T, Kaneko S, Honda M	Hepatitis B virus utilizes a retrograde trafficking route via the trans-Golgi network to avoid lysosomal degradation.	Cell Mol Gastroenterol Hepatol	15(3)	533-558	2023	
149)	Sumiyadorj A, Murai K, <u>Shimakami T</u> , Kuroki K, Nishikawa T, Kakuya M, Yamada A, Wang Y, Ishida A, Shirasaki T, Kawase S, Li YY, Okada H, Nio K, Kawaguchi K, Yamashita T, Sakai Y, Duger D, Mizukoshi E, Honda M, Kaneko S	A single hepatitis B virus genome with a reporter allows the entire viral life cycle to be monitored in primary human hepatocytes.	Hepatol Commun	6(9)	2441-2454	2022	
150)	Shirasaki T, Yamagoe S, <u>Shimakami T</u> , Murai K, Imamura R, Ishii KA, Takayama H, Matsumoto Y, Tajima-Shirasaki N, Nagata N, Shimizu R, Yamanaka S, Abe A, Omura H, Kawaguchi K, Okada H, Yamashita T, Yoshikawa T, Takimoto K, Taharaguchi M, Takatsuka S, Miyazaki Y, Tamai T, Tanabe Y, Kurachi M, Yamamoto Y, Kaneko S, Matsumoto K, Takamura T, Honda M	Leukocyte cell-derived chemotaxin 2 is an antiviral regulator acting through the proto-oncogene MET.	Nat Commun	13(1)	3176	2022	

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
151) 島上哲朗, 佐久間 龍太, 川名 克芳, 黄地 薫, 持田 智, 熊田 博光	サブジェノタイプ 1b の C 型慢性肝炎及び C 型代償性肝硬変患者に対するオムビタスビル/パリタプレビル/リトナビル配合錠の特定使用成績調査 国内臨床試験長期追跡調査.	肝臓	63(7)	319-334	2022	
152) Katagiri D, <u>Kikuchi K</u>	he Impact and Treatment of COVID-19 in Hemodialysis Patients	J Clin Med	12(3)	838	2023	
153) <u>Kikuchi K</u> , Nangaku M, Ryuzaki M, Yamakawa T, Yoshihiro O, Hanafusa N, Sakai K, Kanno Y, Ando R, Shinoda T, Wakino S, Nakamoto H, Takemoto Y, Akizawa T	Effectiveness of SARS-CoV-2 vaccines on hemodialysis patients in Japan: A nationwide cohort study.	Ther Apher Dial	27(1)	19-23	2023	
154) Naito K, <u>Kikuchi K</u> , Watanabe Y, Narita T	Implementation of two novel schemes for patients on dialysis as a response to the COVID-19 surge in Tokyo.	Glob Health Me	4(5)	253-258	2022	
155) Yoshifuji A, Toda M, Ryuzaki M, <u>Kikuchi K</u> , Kawai T, Sakai K, Oyama E, Koinuma M, Katayama K, Uehara Y, Ohmagari N, Kanno Y, Kon H, Shinoda T, Takano Y, Tanaka J, Hora K, Nakazawa Y, Hasegawa N, Hanafusa N, Hinoshita F, Morikane K, Wakino S, Nakamoto H, Takemoto Y	Investigation for the efficacy of COVID-19 vaccine in Japanese CKD patients treated with hemodialysis	Ren Replace Ther	8(1)	39	2022	
156) Yoshifuji A, Ryuzaki M, Uehara Y, Ohmagari N, Kawai T, Kanno Y, <u>Kikuchi K</u> , Kon H, Sakai K, Shinoda T, Takano Y, Tanaka J, Hora K, Nakazawa Y, Hasegawa N, Hanafusa N, Hinoshita F, Morikane K, Wakino S, Nakamoto H, Takemoto Y		Committee report: Questionnaire survey on the treatment of COVID-19 in patients receiving dialysis therapyRen Replace Ther	8(1)	18	2022	
157) Beppu H, Ogawa T, Ishikane M, Kawanishi T, Fukuda T, Sato L, Matsunaga A, Maeda K, Katagiri D, Ishizaka Y, Mitsuya H, Ohmagari N, Yasui F, Kohara M, <u>Kikuchi K</u> , Wakai S	A case of COVID-19 reinfection in a hemodialysis patient: the role of antibody in SARS-CoV-2 infection	CEN Case Rep	9	1-6	2022	
158) <u>Nishina S</u> , Hino K	CD26/DPP4 as a Therapeutic Target in Nonalcoholic Steatohepatitis Associated Hepatocellular Carcinoma	Cancers (Basel)	14(2)	454	2022	



	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
159)	Okamoto S, Miyano K, Choshi T, Sugisawa N, Nishiyama T, Kotouge R, Yamamura M, Sakaguchi M, Kinoshita R, Tomonobu N, Katase N, Sasaki K, <u>Nishina S</u> , Hino K, Kurose K, Oka M, Kubota H, Ueno T, Hirai T, Fujiwara H, Kawai C, Itadani M, Morihara A, Matsushima K, Kanegasaki S, Robert M Hoffman, Yamauchi A, Kuribayashi F	Inhibition of pancreatic cancer-cell growth and metastasis in vivo by a pyrazole compound characterized as a cell-migration inhibitor by an in vitro chemotaxis assay	Biomed Pharmacother	155	113733. doi: 10.1016 /j.biopha .2022.11 3733.	2022	
160)	Imai K, Takai K, Unome S, Maeda T, Hanai T, Shirakami Y, Suetsugu A, <u>Shimizu M</u>	Sustained virological response is the most effective in preventing hepatocellular carcinoma recurrence after curative treatment in hepatitis C virus-positive patients: A study using decision tree analysis.	Int J Transl Med	3	345-354	2022	
161)	Hanai T, Nishimura K, Miwa T, Maeda T, Nakahata Y, Imai K, Suetsugu A, Takai K, <u>Shimizu M</u>	A shortened stroop test to identify covert hepatic encephalopathy and predict overt hepatic encephalopathy in patients with cirrhosis.	J Gastroenterol	57	981-989	2022	○
162)	Ogiso Y, Hanai T, Nishimura K, Miwa T, Maeda T, Imai K, Suetsugu A, Takai K, <u>Shimizu M</u>	Usefulness of the trabecular bone score in assessing the risk of vertebral fractures in patients with cirrhosis.	J Clin Med	11	1562	2022	
163)	Miwa T, Hanai T, Nishimura K, Maeda T, Ogiso Y, Imai K, Suetsugu A, Takai K, Shiraki M, <u>Shimizu M</u>	Handgrip strength stratifies the risk of covert and overt hepatic encephalopathy in patients with cirrhosis.	J Parenter Enteral Nutr	46	858-866	2022	○
164)	Miwa T, Hanai T, Nishimura K, Sakai Y, Imai K, Suetsugu A, Takai K, Shiraki M, Katsumura N, <u>Shimizu M</u>	Survival benefit of l-carnitine supplementation in patients with cirrhosis.	J Parenter Enteral Nutr	46	1326-1334	2022	○
165)	Miwa T, Hanai T, Sakai Y, Kochi T, Katsumura N, <u>Shimizu M</u>	Mac-2-binding protein glycosylation isomer is useful to predict muscle cramps in patients with chronic liver disease.	Medicine (Baltimore)	101	e31145	2022	○
166)	Miwa T, Hanai T, Nishimura K, Unome S, Maeda T, Ogiso Y, Imai K, Suetsugu A, Takai K, <u>Shimizu M</u>	Usefulness of the Global Leadership Initiative on Malnutrition criteria to predict sarcopenia and mortality in patients with chronic liver disease.	Hepato Res	52	928-936	2022	○
167)	Miwa T, Hanai T, Nishimura K, Maeda T, Tajirika S, Imai K, Suetsugu A, Takai K, Yamamoto M, <u>Shimizu M</u>	A simple covert hepatic encephalopathy screening model based on blood biochemical parameters in patients with cirrhosis.	PLoS One	17	e0277829	2022	○
168)	清水雅仁、今井健二、末次淳、杉原潤一、富田栄一	各都道府県における肝疾患対策取り組みの現状	肝臓クリニカルアップデート(別冊)	8	221-224	2022	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
169)	Seko Y, Takahashi H, Toyoda H, Hayashi H, Yamaguchi K, Iwaki M, Yoneda M, Arai T, Shima T, Fujii H, Morishita A, Kawata K, Tomita K, Kawanaka M, Yoshida Y, <u>Ikegami T</u> , Notsumata K, Oeda S, Kamada Y, Sumida Y, Fukushima H, Miyoshi E, Aishima S, Okanoue T, Nakajima A, Itoh Y and Japan Study Group of Nonalcoholic Fatty Liver D	Diagnostic accuracy of enhanced liver fibrosis test for nonalcoholic steatohepatitis-related fibrosis: Multicenter study	Hepato Res	53(4)	312-321	2023	
170)	Kamada Y, Nakamura T, Isobe S, Hosono K, Suama Y, Ohtakaki Y, Nauchi A, Yasuda N, Mitsuta S, Miura K, Yamamoto T, Hosono T, Yoshida A, Kawanishi I, Fukushima H, Kinoshita M, Umeda A, Kinoshita Y, Fukami K, Miyawaki T, Fujii H, Yoshida Y, Kawanaka M, Hyogo H, Morishita A, Hayashi H, Tobita H, Tomita K, <u>Ikegami T</u> , Takahashi H, Yoneda M, Jun DW, Sumida Y, Okanoue T, Nakajima A	JANIT Forum. SWOT analysis of noninvasive tests for diagnosing NAFLD with severe fibrosis: An expert review by the JANIT Forum	J Gastroenterol	58(2)	79-97	2023	
171)	Sato M, Akamatsu M, Shima T, <u>Ikegami T</u> , Yanase M, Mikami S, Imamura J, Nakatsuka T, Tateishi R, Yamauchi N, Ushiku T, Okanoue T, Fujishiro M, Koike K	Impact of novel digital therapeutics system on Nonalcoholic steatohepatitis: The NASH App clinical trial	Am J Gastroenterol		doi: 10.14309/ajg.00000000002143	2023	
172)	Atsukawa M, Tsubota A, Kondo C, Koyano KS, Ishikawa T, Toyoda H, Takaguchi K, Watanabe T, Matsuura K, Ogawa C, Hiraoka A, Okubo H, Tateyama M, Uojima H, Nozaki A, Chuma M, Kato K, Mikami S, Tani J, Morishita A, Kawata K, Tada T, Furuichi Y, Okubo T, Kawano T, Arai T, Kawabe N, Kawamura N, <u>Ikegami T</u> , Nakamuta M, Shigefuku R, Iwasa M, Tanaka Y, Hatano M, Iwakiri K	Risk factors for portopulmonary hypertension in patients with cirrhosis: a prospective, multicenter study	Hepato Int	17(1)	139-149	2023	
173)	Monma T, Iwamoto J, Honda A, Ueda H, Kakizaki F, Yara S, Miyazaki T, <u>Ikegami T</u>	Evaluation of the risk of Clostridium difficile infection using a serum bile acid profile	Metabolites	12(4)	331	2022	
174)	Ueda H, Honda A, Miyazaki T, Morishita Y, Hirayama T, Iwamoto J, Nakamoto N, <u>Ikegami T</u>	Sex-, age-, and organ-dependent improvement of bile acid hydrophobicity by ursodeoxycholic acid treatment: a study using a mouse model with human-like bile acid composition	PLoS ONE	17(7)	e0271308	2022	
175)	Monma T, Iwamoto J, Ueda H, Tamamushi M, Kakizaki F, Konishi N, Yara S, Miyazaki T, Hirayama T, <u>Ikegami T</u> , Honda A	Evaluation of gut dysbiosis using serum and fecal bile acid profiles	World J Clin Cases	10(34)	12484-93	2022	
176)	Miyazaki T, Sasaki S, Toyoda A, Shirai M, <u>Ikegami T</u> , Honda A	Impaired bile acid synthesis in a taurine-deficient cat model	Adv Exp Med Biol	1370	195-203	2022	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
177)	Kawata K, Atsukawa M, Ohta K, Chida T, Noritake H, Arai T, Iwakiri K, Yasuda S, Toyoda H, Okubo T, Hiraoka A, Watanabe T, Uojima H, Nozaki A, Tani J, Morishita A, Kageyama F, Sasada Y, Nagasawa M, Matsushita M, Oyaizu T, Mikami S, <u>Ikegami T</u> , Abe H, Matsuura K, Tanaka Y and Tsubota A	Mac-2-binding protein glycan isomer predicts all malignancies after sustained virological response in chronic hepatitis	Hepato Commu	6	1588-69	2022	
178)	Matsumoto K, Ohfuji S, Abe M, Komori A, Takahashi A, Fujii H, Kawata K, Noritake H, Tadokoro T, Honda A, Asami M, Namisaki T, Ueno M, Sato K, Kakisaka K, Arakawa M, Ito T, Tanaka K, Matsui T, Setsu T, Takamura M, Yasuda S, Katsumi T, Itakura J, Sano T, Tamura Y, Miura R, Arizumi T, Asaoka Y, Uno K, Nishitani A, Ueno Y, Terai S, Takikawa Y, Morimoto Y, Yoshiji H, Mochida S, <u>Ikegami T</u> , Masaki T, Kawada N, Ohira H and Tanaka A	Environmental factors, medical and family history, and comorbidities associated with primary biliary cholangitis in Japan: a multicenter case-control study.	J Gastroenterol	57	19-29	2022	
179)	Maeda K, Takikawa H, Aiso M, Tsuji K, Kagawa T, Watanabe M, Sato K, Sakisaka S, Hiasa Y, Takei Y, Ohira H, Hashimoto E, Ayada M, <u>Ikegami T</u> , Arakawa N, Kusuhara H, Saito Y, Sugiyama Y	Frequency of null genotypes of glutathione S-transferase M1 and T1 in Japanese patients with drug-induced liver injury	Hepato Res	52(10)	882-7	2022	
180)	井上淳, 柿崎暁, 戸島洋貴, 戸所大輔, 小川浩司, <u>池上正</u> , 西村知久, 國方彦志, 是永匡紹	眼科医に対する肝炎ウイルス検査に関するアンケート調査	肝臓	63(2)	87-9	2022	○